Health TrialsbyHealthPanel

Integrated Cancer Repository for Cancer Research

ConditionsPancreatic CancerThyroid CancerLung CancerEsophageal CancerThymus CancerColon CancerRectal CancerGastrointestinal Stromal TumorsAnal CancerBile Duct CancerDuodenal CancerGallbladder CancerGastric CancerLiver CancerSmall Intestine CancerPeritoneal Surface MalignanciesFamilial Adenomatous PolyposisLynch SyndromeBladder CancerKidney CancerPenile CancerProstate CancerTesticular CancerUreter CancerUrethral CancerHypopharyngeal CancerLaryngeal CancerLip CancerOral Cavity CancerNasopharyngeal CancerOropharyngeal CancerParanasal Sinus CancerNasal Cavity CancerSalivary Gland CancerSkin CancerCentral Nervous System TumorCentral Nervous System CancerMesotheliomaBreast CancerLeukemiaMelanomaSarcomaUnknown Primary TumorMultiple MyelomaOvarian CancerEndometrial CancerVaginal CancerNeuroendocrine TumorsPlasma Cell DyscrasiaHealthy Control
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19-110
SponsorUniversity of Nebraska

About this trial

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Diagnosis/history of cancer

Risk for developing cancer or suspicious clinical findings

No history of cancer (normal control registry)

Able to provide informed consent

Disqualifiers

Unable to provide informed consent because of cognitive impairment

Non-English or non-Spanish speaking individuals

Trial population

Any individual who meets the eligibility criteria will be invited to participate in iCaRe2.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Development and Implementation of a Web-based Cancer Collaborative Registry

This is a registry that will continue to accrue participants indefinitely.

Time frame
86 years

Secondary outcomes

1

Procurement and Banking of Excess Biological Material for Future Analysis

This is a registry that will continue to accrue participants indefinitely.

Time frame
86 years

Other outcomes

1

Collection and Banking of Blood, DNA, and Urine Samples for Future Studies

This is a registry that will continue to accrue participants indefinitely.

Time frame
86 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Nebraska

Lead sponsor

Source ClinicalTrials.gov
Apply now